CN117379356B - Nose protecting ointment and preparation method thereof - Google Patents
Nose protecting ointment and preparation method thereof Download PDFInfo
- Publication number
- CN117379356B CN117379356B CN202311684502.6A CN202311684502A CN117379356B CN 117379356 B CN117379356 B CN 117379356B CN 202311684502 A CN202311684502 A CN 202311684502A CN 117379356 B CN117379356 B CN 117379356B
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- phase
- extract
- nasal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000002674 ointment Substances 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 37
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 27
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 24
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 20
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 19
- 229940041616 menthol Drugs 0.000 claims abstract description 19
- 239000003921 oil Substances 0.000 claims abstract description 19
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 16
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 240000004307 Citrus medica Species 0.000 claims abstract description 15
- 241000218394 Magnolia liliiflora Species 0.000 claims abstract description 15
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 13
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 13
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 13
- 235000013871 bee wax Nutrition 0.000 claims abstract description 13
- 239000012166 beeswax Substances 0.000 claims abstract description 13
- 239000006071 cream Substances 0.000 claims abstract description 13
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 13
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 claims abstract description 13
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims abstract description 13
- 239000004200 microcrystalline wax Substances 0.000 claims abstract description 13
- 235000019808 microcrystalline wax Nutrition 0.000 claims abstract description 13
- 239000012188 paraffin wax Substances 0.000 claims abstract description 13
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 13
- 229940087305 limonene Drugs 0.000 claims abstract description 12
- 235000001510 limonene Nutrition 0.000 claims abstract description 12
- 244000025272 Persea americana Species 0.000 claims abstract description 11
- 235000008673 Persea americana Nutrition 0.000 claims abstract description 11
- 150000002632 lipids Chemical class 0.000 claims abstract description 8
- 150000003625 trehaloses Chemical class 0.000 claims abstract description 8
- 229940087291 tridecyl alcohol Drugs 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims description 79
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 31
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 31
- 238000001816 cooling Methods 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- -1 trehalose ester compounds Chemical class 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 12
- 241001251949 Xanthium sibiricum Species 0.000 claims description 12
- 229940116229 borneol Drugs 0.000 claims description 12
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 12
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 12
- 239000000294 eucalyptus globulus labille leaf/twig oil Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 229940047169 astragalus root extract Drugs 0.000 claims description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- SMYKBXMWXCZOLU-UHFFFAOYSA-N tris-decyl benzene-1,2,4-tricarboxylate Chemical compound CCCCCCCCCCOC(=O)C1=CC=C(C(=O)OCCCCCCCCCC)C(C(=O)OCCCCCCCCCC)=C1 SMYKBXMWXCZOLU-UHFFFAOYSA-N 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 239000004367 Lipase Substances 0.000 claims description 6
- 102000004882 Lipase Human genes 0.000 claims description 6
- 108090001060 Lipase Proteins 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 235000019421 lipase Nutrition 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 229920001567 vinyl ester resin Polymers 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- UJRIYYLGNDXVTA-UHFFFAOYSA-N ethenyl hexadecanoate Chemical group CCCCCCCCCCCCCCCC(=O)OC=C UJRIYYLGNDXVTA-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000005022 packaging material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 210000001331 nose Anatomy 0.000 abstract description 13
- 230000003020 moisturizing effect Effects 0.000 abstract description 6
- 239000009636 Huang Qi Substances 0.000 abstract description 5
- 206010052437 Nasal discomfort Diseases 0.000 abstract description 4
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 4
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 3
- 241000218378 Magnolia Species 0.000 abstract description 2
- 208000001780 epistaxis Diseases 0.000 abstract 1
- 239000010642 eucalyptus oil Substances 0.000 abstract 1
- 229940044949 eucalyptus oil Drugs 0.000 abstract 1
- 208000011309 nasal bleeding Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 13
- 238000012856 packing Methods 0.000 description 7
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 201000010105 allergic rhinitis Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000021302 avocado oil Nutrition 0.000 description 2
- 239000008163 avocado oil Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- CMDXMIHZUJPRHG-UHFFFAOYSA-N ethenyl decanoate Chemical compound CCCCCCCCCC(=O)OC=C CMDXMIHZUJPRHG-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 241000928504 Centipeda minima Species 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 241001506766 Xanthium Species 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000009670 cang er zi wan Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- LPUZTLKYAOOFDX-QXMHVHEDSA-N ethenyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC=C LPUZTLKYAOOFDX-QXMHVHEDSA-N 0.000 description 1
- GLVVKKSPKXTQRB-UHFFFAOYSA-N ethenyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC=C GLVVKKSPKXTQRB-UHFFFAOYSA-N 0.000 description 1
- AFSIMBWBBOJPJG-UHFFFAOYSA-N ethenyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC=C AFSIMBWBBOJPJG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a nose protecting ointment and a preparation method thereof. The nasal cream comprises hydrogenated palm kernel oil, tridecyl alcohol trimellitate, avocado fruit lipid, hydrogenated polyisobutene, beeswax, microcrystalline wax, paraffin, butylhydroxytoluene, C12-16 alcohol, hydrogenated lecithin, palmitic acid, trehalose esters, limonene, blue eucalyptus oil, menthol, borneolum Syntheticum, magnolia lilacina bud extract, radix astragali extract, lavender oil, citron fruit oil, tocopheryl acetate, phenoxyethanol, and herba Xanthii extract. Compared with the prior art, the nasal care paste prepared by the invention is added with the magnolia liliflora bud extract, so that capillaries of nasal mucosa can be contracted, and nasal bleeding can be reduced. The radix astragali extract, citron fruit oil, lavender oil and herba Xanthii extract are used as skin conditioner, and can improve and balance skin state, and provide moisturizing, nourishing and relieving effects. Menthol, which helps clear nasal obstruction and alleviate nasal discomfort.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a nose protecting paste and a preparation method thereof.
Background
The nose protecting ointment is one kind of product for protecting and moistening the skin inside nasal cavity. It usually takes the form of a paste or wax, containing a series of ingredients, with soothing, moisturizing and protecting the nasal cavity.
CN116549542a discloses an external ointment for treating acute and chronic allergic rhinitis, which is characterized in that: the external nasal paste comprises the following raw materials in percentage by mass: flos Magnoliae, herba Centipedae, herba Taraxaci, cortex Phellodendri, radix Scutellariae, rhizoma Acori Tatarinowii, radix Angelicae Dahuricae, fructus Xanthii, fructus forsythiae, herba asari, herba Pogostemonis, mentholum, vaseline, vegetable oil, cera flava, and fatty acid monoglyceride. The external rhinitis ointment disclosed by the invention can dispel wind and free the lung, is spicy and fragrant to dredge orifices, and has obvious curative effects on allergic rhinitis, chronic rhinitis, atrophic rhinitis, nasosinusitis, nasal polyp and acute and chronic paranasal sinusitis, and the allergen amount inhaled into the nose is reduced through adsorption and blocking effects.
CN116459289a discloses a traditional Chinese medicine ointment composition for external application of nasal cavity for treating allergic rhinitis, which comprises the following raw materials in parts by weight: 33-40 parts of centipeda minima, 12-12.5 parts of perilla leaf, 12-12.5 parts of cocklebur fruit, 8-9 parts of mint, 8-9 parts of radix angelicae, 8-9 parts of magnolia flower, 8-9 parts of liquorice and 4-6 parts of ephedra; the composition has antiinflammatory, antibacterial, antiallergic, and immunity regulating effects. The Chinese medicine is applied to nasal cavity to treat the disease, so that the medicine is directly contacted with nasal mucosa from the contact, the capillary vessel of the mucosa is expanded, the local blood circulation is quickened, and nerve endings are stimulated to control symptoms such as nasal itching, watery nasal discharge, sneeze and the like caused by mucosa edema and hypersensitivity.
Disclosure of Invention
The invention provides a preparation method of nose protection paste, which comprises the following steps:
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, stirring the phase A raw material at 70-90 ℃ for 5-30min at a rotating speed of 20-100 rpm; then preserving heat at 70-90 ℃ for 20-40min;
s3, cooling to 40-70 ℃, adding the B phase raw material and the C phase raw material, and stirring at the speed of 20-100rpm for 5-30min at the temperature of 40-70 ℃;
s4, filling the materials into various types of packing materials, and cooling to obtain the finished product.
The A phase raw materials comprise hydrogenated palm kernel oil, tridecyl alcohol trimellitate, avocado fruit fat, hydrogenated polyisobutene, beeswax, microcrystalline wax, paraffin, butylhydroxytoluene, C12-16 alcohol, hydrogenated lecithin, palmitic acid, trehalose ester compounds and limonene; the phase B raw materials are as follows: eucalyptus globulus oil, menthol and borneol; the C phase raw material is: magnolia liliflora bud extract, radix astragali extract, lavender oil, citron fruit oil, tocopheryl acetate, phenoxyethanol and Xanthium sibiricum extract.
It is further preferable that the phase A raw materials comprise, by weight, 180-220 parts of hydrogenated palm kernel oil, 100-120 parts of tridecyl trimellitate, 90-100 parts of avocado fruit fat, 80-90 parts of hydrogenated polyisobutene, 70-90 parts of beeswax, 90-110 parts of microcrystalline wax, 20-30 parts of paraffin wax, 0.001-0.005 part of butylhydroxytoluene, 1-2 parts of C12-16 alcohol, 0.5-1.5 parts of hydrogenated lecithin, 0.5-1.5 parts of palmitic acid, 3-6 parts of trehalose ester compounds and 3-6 parts of limonene; the phase B raw materials are as follows: 70-90 parts of eucalyptus globulus oil, 10-30 parts of menthol and 10-30 parts of borneol; the C phase raw material is: 90-110 parts of magnolia liliflora bud extract, 10-30 parts of astragalus root extract, 10-30 parts of lavender oil, 10-30 parts of citron fruit oil, 2-5 parts of tocopheryl acetate, 2-5 parts of phenoxyethanol and 0.1-0.5 part of xanthium sibiricum extract.
It is further preferable that the phase a raw materials are, in parts by weight, 200 parts of hydrogenated palm kernel oil, 110 parts of tridecyl trimellitate, 100 parts of shea butter, 85 parts of hydrogenated polyisobutene, 80 parts of beeswax, 100 parts of microcrystalline wax, 26 parts of paraffin, 0.003 part of butylhydroxytoluene, 1.8 parts of C12-16 alcohol, 0.6 part of hydrogenated lecithin, 0.6 part of palmitic acid, 5 parts of trehalose ester compound, and 4.797 parts of limonene; the phase B raw materials are as follows: 80 parts of eucalyptus globulus oil, 20 parts of menthol and 20 parts of borneol; the C phase raw material is: 100 parts of magnolia liliflora flower bud extract, 20 parts of astragalus root extract, 20 parts of lavender oil, 20 parts of citron fruit oil, 3 parts of tocopheryl acetate, 3 parts of phenoxyethanol and 0.2 part of xanthium sibiricum extract.
Preferably, the preparation method of the trehalose ester compound comprises the following steps: uniformly mixing trehalose, tertiary butanol and dihydro-L-glucosone, adding lipase and fatty acid vinyl ester, and reacting at 50-70deg.C and 100-300rpm for 24-72 hr; cooling, filtering, and concentrating the filtrate under reduced pressure to 1/4 of the original volume; adsorbing and eluting with silica gel column, and drying to obtain trehalose esters.
Further preferably, the preparation method of the trehalose ester compound comprises the following steps: uniformly mixing 0.5-3g of trehalose, 10-20mL of tertiary butanol and 10-20mL of dihydro-L-glucosone, adding 0.5-3g of lipase and 1.5-6g of fatty acid vinyl ester, and reacting for 24-72h at 50-70 ℃ and 100-300 rpm; cooling, filtering, and concentrating the filtrate under reduced pressure to 1/4 of the original volume; adsorbing and eluting with silica gel column, and drying to obtain trehalose esters.
Preferably, the fatty acid vinyl ester is any one of palmitic acid vinyl ester, stearic acid vinyl ester, oleic acid vinyl ester, lauric acid vinyl ester or capric acid vinyl ester. Still more preferably, the fatty acid vinyl ester is vinyl palmitate.
Preferably, the eluent adopted in the elution is dichloromethane and methanol according to the volume ratio of 5-9:1, and mixing.
Hydrogenated palm kernel oil, avocado oil (avocado oil), hydrogenated polyisobutene, beeswax as emollients for providing skin moisturizing, moisturizing and softening effects. A protective film can be formed on the skin surface to prevent evaporation of water and provide moisturization.
Tridecyl trimellitate is a dispersing agent commonly used in cosmetics, has good lubricity, can be used for improving the lubricity and ductility of the cosmetics, and enables the products to be more easily applied and pushed away.
Microcrystalline wax, paraffin wax, and butylhydroxytoluene are used as thickening agents to increase the viscosity, and rheological properties of the paste.
C12-16 alcohol, hydrogenated lecithin and palmitic acid are used as emulsifying agents to improve the texture and touch of the paste, so that the paste is easier to smear and absorb. The softness, smoothness and viscosity of the paste can also be increased, and better use experience is provided.
Borneol, which is one of skin conditioning agents, can provide a pleasant feel to the skin.
The radix astragali extract, citron fruit oil, lavender oil and herba Xanthii extract are used as skin conditioner, and can improve and balance skin state, and provide moisturizing, nourishing and relieving effects.
Tocopheryl acetate, one of the antioxidants, helps to protect the skin from oxidative stress by protecting against free radical damage. Also has antiinflammatory and relieving effects, and can relieve skin discomfort and inflammatory reaction.
The phenoxyethanol, which is one of the preservatives, has broad-spectrum antibacterial and antifungal properties, can effectively inhibit the growth of microorganisms in cosmetics, and prolongs the shelf life of the products.
The magnolia liliflora flower bud extract can shrink capillaries of nasal mucosa, so that nasal hemorrhage can be reduced, and an antiallergic effect can be achieved, so that the auxiliary treatment of allergic rhinitis can be achieved.
The eucalyptus globulus oil contains abundant antibacterial and antiseptic components, and can effectively inhibit acne. It has histamine inhibiting effect and can be used as antiallergic agent. In addition, it has effects of promoting keratinocyte proliferation, scavenging free radicals, and preventing aging.
Menthol, derived from a natural herbal extract, can be used for nasal care. It can help clear nasal obstruction and alleviate nasal discomfort. The peppermint essential oil also has sedative and relaxing effects, and can help you relax mind and body and relieve stress and anxiety. Meanwhile, menthol has good effect of promoting skin penetration.
The limonene has good permeability, can help other active ingredients to better permeate into skin, and improves the absorption effect of the active ingredients of the paste.
The invention has the beneficial effects that:
1. compared with the prior art, the magnolia liliflora flower bud extract can shrink capillaries of nasal mucosa, so that nasal hemorrhage can be reduced, and an antiallergic effect can be achieved, so that the auxiliary treatment of allergic rhinitis can be achieved. The radix astragali extract, citron fruit oil, lavender oil and herba Xanthii extract are used as skin conditioner, and can improve and balance skin state, and provide moisturizing, nourishing and relieving effects. Menthol, which helps clear nasal obstruction and alleviate nasal discomfort. Meanwhile, menthol has good effect of promoting skin penetration.
2. Compared with the prior art, the invention can effectively improve the skin permeation effect of the nose-protecting cream by the synergistic use of the trehalose palmitate compound synthesized by the trehalose and the palmitic acid and the limonene.
Detailed Description
The invention is further illustrated with reference to specific embodiments.
The magnolia liliflora flower bud extract, the astragalus root extract and the xanthium sibiricum extract in the embodiment of the invention are all products obtained by a conventional water extraction method.
Example 1
A preparation method of the nose protection paste comprises the following steps:
the raw materials are divided into a phase A, a phase B and a phase C, and the total weight of the raw materials is 1000 g:
the A phase raw material is: 209.797g of hydrogenated palm kernel oil, 110g of tridecyl trimellitate, 100g of avocado fruit fat, 85g of hydrogenated polyisobutene, 80g of beeswax, 100g of microcrystalline wax, 26g of paraffin, 0.003g of butylhydroxytoluene, 1.8g of C12-16 alcohol, 0.6g of hydrogenated lecithin and 0.6g of palmitic acid;
the phase B raw materials are as follows: 80g of eucalyptus globulus oil, 20g of menthol and 20g of borneol;
the C phase raw material is: 100g of magnolia liliflora bud extract, 20g of astragalus root extract, 20g of lavender oil, 20g of citron fruit oil, 3g of tocopheryl acetate, 3g of phenoxyethanol and 0.2g of xanthium sibiricum extract;
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, sequentially adding the phase A raw materials into a stirring pot, and stirring at the temperature of 85 ℃ for 10min at the rotating speed of 50 rpm; then preserving the temperature at 85 ℃ for 25min;
s3, cooling to 60 ℃, adding the B phase raw material and the C phase raw material, and stirring at the temperature of 60 ℃ for 10min at the rotating speed of 50 rpm;
s4, filling the materials into various types of packing materials, and cooling to obtain the finished product.
Example 2
A preparation method of the nose protection paste comprises the following steps:
the raw materials are divided into a phase A, a phase B and a phase C, and the total weight of the raw materials is 1000 g:
the A phase raw material is: 200g of hydrogenated palm kernel oil, 110g of tridecyl trimellitate, 100g of avocado fruit lipid, 85g of hydrogenated polyisobutene, 80g of beeswax, 100g of microcrystalline wax, 26g of paraffin, 0.003g of butylhydroxytoluene, 1.8g of C12-16 alcohol, 0.6g of hydrogenated lecithin, 0.6g of palmitic acid and 9.797g of trehalose ester compound;
the phase B raw materials are as follows: 80g of eucalyptus globulus oil, 20g of menthol and 20g of borneol;
the C phase raw material is: 100g of magnolia liliflora bud extract, 20g of astragalus root extract, 20g of lavender oil, 20g of citron fruit oil, 3g of tocopheryl acetate, 3g of phenoxyethanol and 0.2g of xanthium sibiricum extract;
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, sequentially adding the phase A raw materials into a stirring pot, and stirring at the temperature of 85 ℃ for 10min at the rotating speed of 50 rpm; then preserving the temperature at 85 ℃ for 25min;
s3, cooling to 60 ℃, adding the B phase raw material and the C phase raw material, and stirring at the temperature of 60 ℃ for 10min at the rotating speed of 50 rpm;
s4, filling the materials into various types of packing materials, and cooling to obtain the finished product.
The preparation method of the trehalose ester compound comprises the following steps: 1g of trehalose, 15mL of tertiary butanol and 15mL of dihydro-L-glucosone are uniformly mixed, 1g of lipase and 3.3g of vinyl palmitate are added for reaction for 48 hours at 60 ℃ and 200 rpm; cooling, filtering, and concentrating the filtrate under reduced pressure to 1/4 of the original volume; adsorbing and eluting with silica gel column, and drying to obtain trehalose esters.
The eluent adopted by the elution is dichloromethane and methanol according to the volume ratio of 9:1, and mixing.
Example 3
A preparation method of the nose protection paste comprises the following steps:
the raw materials are divided into a phase A, a phase B and a phase C, and the total weight of the raw materials is 1000 g:
the A phase raw material is: 200g of hydrogenated palm kernel oil, 110g of tridecyl trimellitate, 100g of avocado fruit lipid, 85g of hydrogenated polyisobutene, 80g of beeswax, 100g of microcrystalline wax, 26g of paraffin, 0.003g of butylhydroxytoluene, 1.8g of C12-16 alcohol, 0.6g of hydrogenated lecithin, 0.6g of palmitic acid and 9.797g of trehalose ester compound;
the phase B raw materials are as follows: 80g of eucalyptus globulus oil, 20g of menthol and 20g of borneol;
the C phase raw material is: 100g of magnolia liliflora bud extract, 20g of astragalus root extract, 20g of lavender oil, 20g of citron fruit oil, 3g of tocopheryl acetate, 3g of phenoxyethanol and 0.2g of xanthium sibiricum extract;
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, sequentially adding the phase A raw materials into a stirring pot, and stirring at the temperature of 85 ℃ for 10min at the rotating speed of 50 rpm; then preserving the temperature at 85 ℃ for 25min;
s3, cooling to 60 ℃, adding the B phase raw material and the C phase raw material, and stirring at the temperature of 60 ℃ for 10min at the rotating speed of 50 rpm;
s4, filling the materials into various types of packing materials, and cooling to obtain the finished product.
The preparation method of the trehalose ester compound comprises the following steps: 1g of trehalose, 15mL of tertiary butanol and 15mL of dihydro-L-glucosone are uniformly mixed, and then 1g of lipase and 3.3g of vinyl decanoate are added for reaction for 48 hours at 60 ℃ and 200 rpm; cooling, filtering, and concentrating the filtrate under reduced pressure to 1/4 of the original volume; adsorbing and eluting with silica gel column, and drying to obtain trehalose esters.
The eluent adopted by the elution is dichloromethane and methanol according to the volume ratio of 9:1, and mixing.
Example 4
A preparation method of the nose protection paste comprises the following steps:
the raw materials are divided into a phase A, a phase B and a phase C, and the total weight of the raw materials is 1000 g:
the A phase raw material is: 200g of hydrogenated palm kernel oil, 110g of tridecyl trimellitate, 100g of avocado fruit lipid, 85g of hydrogenated polyisobutene, 80g of beeswax, 100g of microcrystalline wax, 26g of paraffin, 0.003g of butylhydroxytoluene, 1.8g of C12-16 alcohol, 0.6g of hydrogenated lecithin, 0.6g of palmitic acid and 9.797g of trehalose;
the phase B raw materials are as follows: 80g of eucalyptus globulus oil, 20g of menthol and 20g of borneol;
the C phase raw material is: 100g of magnolia liliflora bud extract, 20g of astragalus root extract, 20g of lavender oil, 20g of citron fruit oil, 3g of tocopheryl acetate, 3g of phenoxyethanol and 0.2g of xanthium sibiricum extract;
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, sequentially adding the phase A raw materials into a stirring pot, and stirring at the temperature of 85 ℃ for 10min at the rotating speed of 50 rpm; then preserving the temperature at 85 ℃ for 25min;
s3, cooling to 60 ℃, adding the B phase raw material and the C phase raw material, and stirring at the temperature of 60 ℃ for 10min at the rotating speed of 50 rpm;
s4, filling the materials into various types of packing materials, and cooling to obtain the finished product.
Example 5
A preparation method of the nose protection paste comprises the following steps:
the raw materials are divided into a phase A, a phase B and a phase C, and the total weight of the raw materials is 1000 g:
the A phase raw material is: 200g of hydrogenated palm kernel oil, 110g of tridecyl trimellitate, 100g of avocado fruit lipid, 85g of hydrogenated polyisobutene, 80g of beeswax, 100g of microcrystalline wax, 26g of paraffin, 0.003g of butylhydroxytoluene, 1.8g of C12-16 alcohol, 0.6g of hydrogenated lecithin, 0.6g of palmitic acid and 9.797g of limonene;
the phase B raw materials are as follows: 80g of eucalyptus globulus oil, 20g of menthol and 20g of borneol;
the C phase raw material is: 100g of magnolia liliflora bud extract, 20g of astragalus root extract, 20g of lavender oil, 20g of citron fruit oil, 3g of tocopheryl acetate, 3g of phenoxyethanol and 0.2g of xanthium sibiricum extract;
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, sequentially adding the phase A raw materials into a stirring pot, and stirring at the temperature of 85 ℃ for 10min at the rotating speed of 50 rpm; then preserving the temperature at 85 ℃ for 25min;
s3, cooling to 60 ℃, adding the B phase raw material and the C phase raw material, and stirring at the temperature of 60 ℃ for 10min at the rotating speed of 50 rpm;
s4, filling the materials into various types of packing materials, and cooling to obtain the finished product.
Example 6
A preparation method of the nose protection paste comprises the following steps:
the raw materials are divided into a phase A, a phase B and a phase C, and the total weight of the raw materials is 1000 g:
the A phase raw material is: 200g of hydrogenated palm kernel oil, 110g of tridecyl trimellitate, 100g of avocado fruit lipid, 85g of hydrogenated polyisobutene, 80g of beeswax, 100g of microcrystalline wax, 26g of paraffin, 0.003g of butylhydroxytoluene, 1.8g of C12-16 alcohol, 0.6g of hydrogenated lecithin, 0.6g of palmitic acid, 5g of trehalose ester compound and 4.797g of limonene;
the phase B raw materials are as follows: 80g of eucalyptus globulus oil, 20g of menthol and 20g of borneol;
the C phase raw material is: 100g of magnolia liliflora bud extract, 20g of astragalus root extract, 20g of lavender oil, 20g of citron fruit oil, 3g of tocopheryl acetate, 3g of phenoxyethanol and 0.2g of xanthium sibiricum extract;
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, sequentially adding the phase A raw materials into a stirring pot, and stirring at the temperature of 85 ℃ for 10min at the rotating speed of 50 rpm; then preserving the temperature at 85 ℃ for 25min;
s3, cooling to 60 ℃, adding the B phase raw material and the C phase raw material, and stirring at the temperature of 60 ℃ for 10min at the rotating speed of 50 rpm;
s4, filling the materials into various types of packing materials, and cooling to obtain the finished product.
The preparation method of the trehalose ester compound comprises the following steps: 1g of trehalose, 15mL of tertiary butanol and 15mL of dihydro-L-glucosone are uniformly mixed, 1g of lipase and 3.3g of vinyl palmitate are added for reaction for 48 hours at 60 ℃ and 200 rpm; cooling, filtering, and concentrating the filtrate under reduced pressure to 1/4 of the original volume; adsorbing and eluting with silica gel column, and drying to obtain trehalose esters.
The eluent adopted by the elution is dichloromethane and methanol according to the volume ratio of 9:1, and mixing.
Test example 1
By follow-up tests on the population (children 50, adults 50) using the nasal cream of example 6. The paste has obvious curative effect, especially faster and better effect for children.
Test example 2
Transdermal absorption test: cutting Corii Sus Domestica to size of about 2.5cm×2.5cm, fixing on vertical Franz diffusion cell equipped with magnetic stirrer, facing horny layer side toward supply cell, facing dermis side toward receiving cell (volume 18mL, inner diameter 2 cm), and applying nasal cream (application amount 0.1 g/cm) on horny layer side 2 ) The supply tank and the receiving tank are connected and fixed, the pH7.4 phosphate buffer preheated to 37 ℃ is added into the receiving tank, the constant temperature 37 ℃ water bath and magnetic stirring are started, timing is started, 2mL is sampled from the receiving tank after 2h, and the same amount of pH7.4 phosphate buffer at 37 ℃ is timely supplemented. The received solution was filtered through a 0.45 μm filter, and the content of menthol in each sample solution was calculated by measuring, and the cumulative passage of menthol was calculated from the measured content.
TABLE 1
| 2h cumulative transmittance | |
| Example 1 | 4.12% |
| Example 2 | 7.27% |
| Example 3 | 6.18% |
| Example 4 | 3.18% |
| Example 5 | 7.06% |
| Example 6 | 9.31% |
As can be seen from the above table, the transdermal absorption effect of the nasal cream of example 6 is significantly better than that of the nasal cream of example 2 or 5. The reasons for this may be: meanwhile, compared with the independently added trehalose ester compound or limonene, the added trehalose ester compound and limonene have better synergistic effect. Meanwhile, the nasal cream of example 5 had a better percutaneous absorption effect than that of example 2. The possible reasons for this are: compared with trehalose ester compounds synthesized by trehalose and palmitic acid, the trehalose ester compounds synthesized by trehalose and palmitic acid have stronger destructiveness on the integrity of cell monolayers, can better promote the redistribution of linker proteins, and realize better permeation promotion.
Test example 3
Stability test
The phenomenon of alcohol-oil separation of pastes is due to the presence of oil and alcohol components in some pastes, which may separate after a long period of time. Typically, the surface is a layer of apparent grease on the surface of the paste.
100g of the pastes of examples 1 to 6 were each placed in a transparent glass bottle and sealed, and stored at 48℃and the time for the paste to exhibit an alcohol-oil separation phenomenon was recorded.
TABLE 2
| Occurrence of oil-alcohol separation | |
| Example 1 | 42 days |
| Example 2 | 125 days |
| Example 3 | 96 days |
| Example 4 | 45 days |
| Example 5 | 41 days |
| Example 6 | 116 days |
From the above table, it can be seen that the addition of trehalose esters in the nasal cream in examples 2, 3 and 6 can effectively improve the oleyl alcohol separation effect of the nasal cream. The possible reasons for this are: the trehalose ester compound can form a colloid structure with other components in the nose protecting cream, increase the viscosity of the cream, and prevent the deposition and phase separation of the components. The trehalose ester compound may form a film on the liquid interface, reduce the surface tension of the liquid interface, reduce the mutual attraction between liquid drops, prevent the aggregation and sedimentation of oil drops, and increase the stability of paste.
The foregoing describes in detail preferred embodiments of the present invention. It should be understood that numerous modifications and variations can be made in accordance with the concepts of the invention by one of ordinary skill in the art without undue burden. Therefore, all technical solutions which can be obtained by logic analysis, reasoning or limited experiments based on the prior art by the person skilled in the art according to the inventive concept shall be within the scope of protection defined by the claims.
Claims (4)
1. The preparation method of the nose protection paste is characterized by comprising the following steps:
s1, weighing raw materials according to a formula, and cleaning and sterilizing equipment;
s2, stirring the phase A raw material at 70-90 ℃ for 5-30min at a rotating speed of 20-100 rpm; then preserving heat at 70-90 ℃ for 20-40min;
s3, cooling to 40-70 ℃, adding the B phase raw material and the C phase raw material, and stirring at the speed of 20-100rpm for 5-30min at the temperature of 40-70 ℃;
s4, filling the materials into various types of packaging materials, and cooling to obtain the finished product;
the phase A raw materials comprise 180-220 parts of hydrogenated palm kernel oil, 100-120 parts of tridecyl alcohol trimellitate, 90-100 parts of avocado fruit lipid, 80-90 parts of hydrogenated polyisobutene, 70-90 parts of beeswax, 90-110 parts of microcrystalline wax, 20-30 parts of paraffin, 0.001-0.005 part of butylhydroxytoluene, 1-2 parts of C12-16 alcohol, 0.5-1.5 parts of hydrogenated lecithin, 0.5-1.5 parts of palmitic acid, 3-6 parts of trehalose ester compounds and 3-6 parts of limonene; the phase B raw materials are as follows: 70-90 parts of eucalyptus globulus oil, 10-30 parts of menthol and 10-30 parts of borneol; the C phase raw material is: 90-110 parts of magnolia liliflora bud extract, 10-30 parts of astragalus root extract, 10-30 parts of lavender oil, 10-30 parts of citron fruit oil, 2-5 parts of tocopheryl acetate, 2-5 parts of phenoxyethanol and 0.1-0.5 part of xanthium sibiricum extract;
the preparation method of the trehalose ester compound comprises the following steps: uniformly mixing 0.5-3g of trehalose, 10-20mL of tertiary butanol and 10-20mL of dihydro-L-glucosone, adding 0.5-3g of lipase and 1.5-6g of fatty acid vinyl ester, and reacting for 24-72h at 50-70 ℃ and 100-300 rpm; cooling, filtering, and concentrating the filtrate under reduced pressure to 1/4 of the original volume; adsorbing and eluting with silica gel column, and drying to obtain trehalose esters;
the fatty acid vinyl ester is palmitic acid vinyl ester.
2. The method for preparing the nasal cream according to claim 1, wherein: the A phase raw materials comprise, by weight, 200 parts of hydrogenated palm kernel oil, 110 parts of tridecyl trimellitate, 100 parts of avocado fruit lipid, 85 parts of hydrogenated polyisobutene, 80 parts of beeswax, 100 parts of microcrystalline wax, 26 parts of paraffin, 0.003 part of butylhydroxytoluene, 1.8 parts of C12-16 alcohol, 0.6 part of hydrogenated lecithin, 0.6 part of palmitic acid, 5 parts of trehalose ester compounds and 4.797 parts of limonene; the phase B raw materials are as follows: 80 parts of eucalyptus globulus oil, 20 parts of menthol and 20 parts of borneol; the C phase raw material is: 100 parts of magnolia liliflora flower bud extract, 20 parts of astragalus root extract, 20 parts of lavender oil, 20 parts of citron fruit oil, 3 parts of tocopheryl acetate, 3 parts of phenoxyethanol and 0.2 part of xanthium sibiricum extract.
3. The method for preparing the nasal cream according to claim 1, wherein: the eluent adopted by the elution is dichloromethane and methanol according to the volume ratio of 5-9:1, and mixing.
4. A nose protection paste, which is characterized in that: a method according to any one of claims 1 to 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311684502.6A CN117379356B (en) | 2023-12-11 | 2023-12-11 | Nose protecting ointment and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311684502.6A CN117379356B (en) | 2023-12-11 | 2023-12-11 | Nose protecting ointment and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117379356A CN117379356A (en) | 2024-01-12 |
| CN117379356B true CN117379356B (en) | 2024-03-12 |
Family
ID=89470561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311684502.6A Active CN117379356B (en) | 2023-12-11 | 2023-12-11 | Nose protecting ointment and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117379356B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761450A (en) * | 2003-02-13 | 2006-04-19 | 株式会社林原生物化学研究所 | Skin preparation for external use characterized by containing sugar derivative of a,a-trehalose |
| CN104274633A (en) * | 2014-01-13 | 2015-01-14 | 北京德默高科医药技术有限公司 | Composition for cleaning and protecting nose |
| CN116536379A (en) * | 2023-06-19 | 2023-08-04 | 暨南大学 | Preparation method and application of trehalose fatty acid monoester and diester |
-
2023
- 2023-12-11 CN CN202311684502.6A patent/CN117379356B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761450A (en) * | 2003-02-13 | 2006-04-19 | 株式会社林原生物化学研究所 | Skin preparation for external use characterized by containing sugar derivative of a,a-trehalose |
| CN104274633A (en) * | 2014-01-13 | 2015-01-14 | 北京德默高科医药技术有限公司 | Composition for cleaning and protecting nose |
| CN116536379A (en) * | 2023-06-19 | 2023-08-04 | 暨南大学 | Preparation method and application of trehalose fatty acid monoester and diester |
Non-Patent Citations (1)
| Title |
|---|
| 朱照静等.药剂学.第四军医大学出版社,2007,第324-326页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117379356A (en) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101236946B1 (en) | Cosmetic Composition Comprising Naturalplant Extract for Alleviating Atopic Dermatitis | |
| KR20080002279A (en) | Lip cosmetic composition for atopy skin | |
| CN110179730B (en) | Repair cream | |
| KR20200029981A (en) | Composition for Prevention or Improving of Atopic Dermatitis and manufacturing method thereof | |
| CN109498523B (en) | Anti-chapping skin care product and preparation thereof | |
| CN111195333A (en) | Composition and sleep cream for improving sleep, and preparation method and use method thereof | |
| CN106511211A (en) | Anti-inflammatory and anti-acne skin care lotion and preparation method thereof | |
| KR20090131399A (en) | Cosmetic composition of natural plant mixture extracts having anti-inflammation effect | |
| CN117379356B (en) | Nose protecting ointment and preparation method thereof | |
| CN106389162A (en) | Massage oil emulsion containing argy wormwood leaf essential oil and preparation method of massage oil emulsion | |
| CN102872240B (en) | Compound essential oil for relaxing and activating collaterals | |
| CN110721101A (en) | Self-prepared two-component essence cream and preparation method thereof | |
| CN111973501A (en) | Ceramide activation milk and preparation method thereof | |
| CN114344219A (en) | Aromatic plant composition for treating red swelling, itching and pain of skin and preparation method thereof | |
| CN112494350B (en) | Organic emulsion and preparation method thereof | |
| CN109364011A (en) | It is a kind of to be dissipated and preparation method thereof so that the coated of whitening spot-removing new eight is white | |
| CN107854681A (en) | A kind of anti-inflammatory composition and preparation method thereof | |
| CN114306410A (en) | Lithospermum ointment and preparation method and application thereof | |
| CN106420991A (en) | Skin care massage oil containing tea tree essential oil | |
| KR101121736B1 (en) | Medicinal herb extracts for skin whitening, a method of manufacturing the same and skin whitening cosmetics containing the same | |
| CA3083769C (en) | Composition for sebum control and pore minimizing | |
| KR20210143993A (en) | Composition comprising dokdo aster oil | |
| CN108703915A (en) | It is a kind of using rose extract as the moisture retention skin care item of main active component | |
| KR102576693B1 (en) | Cosmetic composition comprising infused oils of calendular and mixed extracts of plants for moisturizing skin | |
| KR102482389B1 (en) | Cosmetic composition for relieving skin troubles or improving atopic dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |